上述融资客大手笔净买入的科创板股中，从最新融资余额占流通市值比例看，算术平均值为4.09%，融 资余额占比最高的是金博股份，该股最新融资余额为5.94亿元，占流通市值的比例为10.74%，融资余额 占比较高的还有有方科技、航天南湖、中科蓝讯，占比分别为9.89%、8.22%、8.13%。（数据宝） | 代码 | 简称 | 最新融资余额（万 | 环比增减金额（万 | 环比增减 | 当日涨跌幅 | | --- | --- | --- | --- | --- | --- | | | | 元） | 元） | （%） | （%） | | 688256 | 寒武纪 | 560827.93 | 14126.87 | 2.58 | 0.84 | | 688521 | 芯原股 份 | 94100.00 | 11464.81 | 13.87 | 1.82 | | 688552 | 航天南 湖 | 26910.66 | 4753.01 | 21.45 | -2.69 | | 688299 | 长阳科 技 | 44152.15 | 3734.87 | 9.24 | 3.93 | | 688608 | 恒玄科 | 53887.28 | ...

Core Insights - The successful completion of the project marks a significant step for Changyang Technology from technical research to commercial application [1][2] - The project focuses on the development of low-cost CBDO and high Tg, impact-resistant transparent copolyester, aligning with the trend of green manufacturing and sustainable development [1] Group 1: Project Overview - The project is part of the 2021 National Key R&D Program aimed at the preparation and industrialization of low-cost, high-performance bio-based polyesters and polycarbonates [1] - The project team has successfully developed a low-cost CBDO synthesis process and has made breakthroughs in the formulation and preparation technology of copolyester films [1] Group 2: Technical Achievements - Key performance indicators such as visible light transmittance, mechanical strength, and weather resistance of the products have met the contractual requirements [1] - The expert review team acknowledged the project's demonstration effect in collaborative innovation between industry, academia, and research [1] Group 3: Future Directions - Changyang Technology aims to leverage its extensive technical expertise in optical film materials to accelerate the research and application of bio-based materials in functional films [2] - The company is committed to supporting China's transition from a "material power" to a "material strong power" [2]

证券代码：688299 证券简称：长阳科技 公告编号：2025-033 宁波长阳科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 13 日 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事7人，以现场结合通讯方式出席7人； 2、 公司在任监事3人，以现场方式出席3人； 3、 董事会秘书章殷洪先生出席了本次会议；高级管理人员列席了本次会议。 二、 议案审议情况 （一） 非累积投票议案 （二） 股东大会召开的地点：宁波市江北区庆丰路 999 号公司一楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 58 | | --- | --- | | 普通股股东人数 | 58 | | 2、出席会议的股东所持有的表决权数量 | 57,820,293 | | 普通股 ...

国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 Grandall Law Firm (Shanghai) 中国 上海 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼，200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China, 200085 电话/TEL: (8621) 5234-1668 传真/FAX: (8621) 5234-1670 关于宁波长阳科技股份有限公司 2024年年度股东大会的法律意见书 致：宁波长阳科技股份有限公司 国浩律师（上海）事务所（以下简称"本所"）接受宁波长阳科技股份有限公 司（以下简称"公司"）委托，指派本所律师出席公司 2024 年年度股东大会（以 下简称"本次股东大会"）。本所律师根据《中华人民共和国证券法》（以下简称 "《证券法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、《上 市公司股东会规则》（以下简称"《股东会规则》"）等法律、法规、部门规章和 规范性文件以及《宁波长阳科技股份有限公司章程》（以下简称"《公司章程》"） ...

Group 1 - The State Council Information Office will hold a press conference regarding the "Promotion Law of Private Economy of the People's Republic of China" on May 8, with officials from various government departments providing insights and answering questions [2] - The Ministry of Commerce will hold its first regular press conference of May on the same day, focusing on recent key work in the business sector [3] Group 2 - Starting from May 8, 2025, the People's Bank of China announced a reduction of 0.25 percentage points in the personal housing provident fund loan interest rates, with the new rates set at 2.1% for loans of 5 years or less and 2.6% for loans over 5 years for the first home [4] - A total of 10 companies will have their restricted shares unlocked today, with a combined unlock volume of 246 million shares, amounting to a market value of 1.071 billion yuan based on the latest closing prices [4] - Among the companies with significant unlock volumes, Kangmei Pharmaceutical, Guotai Haitong, and Changyang Technology lead with unlock volumes of 209 million shares, 27.8 million shares, and 3.66 million shares respectively [4] Group 3 - A total of 86 companies disclosed stock repurchase progress on May 8, with 89 related announcements made [5] - Notably, Guomai Culture proposed a repurchase of up to 100 million yuan, while Zhiyuan New Energy plans to repurchase up to 66 million yuan [6] - Two companies had repurchase plans exceeding 10 million yuan approved by their shareholders' meetings, with the highest repurchase amounts proposed by Zhongke Xingtou, Shudao Equipment, and Nanjing Public Utilities [6]

宁波长阳科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688299 证券简称：长阳科技 宁波长阳科技股份有限公司 2024 年年度股东大会会议资料 2025 年 5 月 宁波长阳科技股份有限公司 2024 年年度股东大会会议资料 宁波长阳科技股份有限公司 2024 年年度股东大会会议资料目录 | 宁波长阳科技股份有限公司 | 2024 年年度股东大会会议须知 3 | | --- | --- | | 宁波长阳科技股份有限公司 | 年年度股东大会会议议程 5 2024 | | 议案一：关于公司 2024 | 年年度报告及摘要的议案 7 | | 议案二：关于公司独立董事 | 2024 年度述职报告的议案 8 | | 议案三：关于公司 2024 | 年度董事会工作报告的议案 9 | | 议案四：关于公司 2024 | 年度监事会工作报告的议案 10 | | 议案五：关于公司 2024 | 年度财务决算报告的议案 11 | | 议案六：关于公司 2024 | 年度利润分配预案的议案 12 | | 议案七：关于公司 2025 | 年度财务预算报告的议案 13 | | 议案八：关于公司 2024 | 年度募 ...

Summary of Changyang Technology Conference Call Company Overview - **Company**: Changyang Technology - **Industry**: Display materials, specifically focusing on reflective films, optical base films, and new product development in solid-state battery materials Key Points Financial Performance - **Q1 2025 Profit Growth**: Changyang Technology reported a 72% year-on-year profit increase, attributed to improved gross margins in reflective films and significant reduction in losses from the gel film business [2][6] - **Revenue and Profit Figures**: Q1 2025 revenue was 267 million yuan, with a net profit of 14.16 million yuan, despite a 14.97% decline in overall revenue compared to the previous year [3][6] - **Reflective Film Revenue**: Reflective film revenue decreased by approximately 4% year-on-year, but gross margin improved from 36.8% to 37.34% [3][23] Business Segments - **Reflective Film Business**: Expected to maintain single-digit growth for the year, driven by increased demand for large-sized TVs and new customer introductions [2][7] - **Optical Base Film Performance**: Q1 revenue was 17.9 million yuan, down 400,000 yuan year-on-year, with a negative gross margin of 11% due to underutilization of capacity [2][8][9] - **Gel Film and Separator Business**: Losses in gel film and separator segments have narrowed, contributing to overall profit growth [2][6][28] New Product Development - **Solid-State Battery Composite Films**: The company is advancing in the development of solid-state battery composite films, with major clients including Panasonic, Samsung SDI, and CATL. Small-scale deliveries are expected by 2027 [2][12][14] - **CPI Product Development**: Progress is slightly behind schedule, with plans to achieve stable mass production by the end of the year. One production line is planned for this year [4][16][19] Market Dynamics - **Impact of Oil Prices**: The decline in oil prices and the increase in the proportion of small-sized products are expected to enhance gross margins further [2][7] - **Competitive Landscape**: The optical base film market faces intense competition, particularly in low-end products, which may slow margin improvements [27] Strategic Focus - **Long-term Strategy**: The company is focusing on solid-state battery composite films and CPI products while stabilizing existing reflective and optical base film businesses. Non-core segments are being reduced to enhance overall health [4][17][31] - **Financial Management**: The company aims to optimize financial management by strategically disposing of non-core assets and focusing on emerging fields [29][30] Future Outlook - **Production Capacity and Cost**: The production line for solid-state battery composite films has a capacity of 50 million square meters, with a low investment cost of approximately 50-60 million yuan [14][18] - **Market Demand**: Short-term demand for solid-state battery materials is expected to be limited, but pricing remains favorable due to low supply [18][19] Additional Insights - **Downstream Verification**: The verification process for new products is slightly delayed, with expectations for small batch orders in the following year [19][21] - **Asset Management**: The company anticipates a significant reduction in losses from the separator and gel film businesses due to improved asset management strategies [28] This summary encapsulates the key insights from the conference call, highlighting the company's financial performance, business segments, new product developments, market dynamics, strategic focus, and future outlook.

Policy Developments - Hainan Province has released a plan to enhance the quality of generic drugs, supporting the expedited registration and market entry of first generic products, particularly those that are urgently needed in clinics or have high prices or supply shortages [1] - The plan includes strengthening supervision of entrusted production and supporting consistency evaluations for the quality and efficacy of generic drugs, which will improve overall drug quality and ensure public safety [1] Drug and Device Approvals - Huasheng Technology's Sanqi Tongshu Capsules have been approved as the first secondary protected traditional Chinese medicine by the National Medical Products Administration, enhancing the company's core competitiveness in treating cardiovascular diseases [2] - United Imaging Healthcare's digital subtraction angiography system (DSA) uAngioAVIVA has received FDA approval, marking it as the first and only domestic DSA device allowed in the U.S. market [3] - Warner Pharmaceuticals has received a listing approval notice for potassium sulfate, which will enrich the company's product line and enhance its core competitiveness [4] - Xinhua Medical has obtained a Class II medical device registration certificate for its multi-chamber cleaning and disinfection device, which significantly reduces processing time compared to fully automatic devices [5] Financial Reports - Kelun Pharmaceutical reported a 29.42% year-on-year decline in revenue for Q1 2025, totaling 4.389 billion yuan, with a net profit decrease of 43.07% to 584 million yuan [6][7] - AstraZeneca's Q1 2025 revenue reached $13.588 billion, a 10% increase year-on-year, driven by double-digit growth in oncology and biopharmaceuticals [8] Capital Market Activities - Koser Medical Technology has completed nearly 100 million yuan in B+ round financing, which will be used for core product development and global market expansion [9] - Xellar Biosystems has secured several million yuan in strategic investment from XtalPi, aimed at accelerating the development of its organ-on-chip technology and expanding international collaborations [10] Industry Developments - Chen Yuqing has been appointed as the new chairman of Fosun Pharma, succeeding Wu Yifang, and will oversee the company's strategic development and organizational growth [11] - Merck has announced a $1 billion investment to build a production facility in Wilmington, Delaware, aimed at producing the next generation of biopharmaceuticals, including Keytruda [12] - Prilenia has entered a collaboration agreement with Ferrer for the oral sigma-1 receptor agonist Pridopidine, with a total deal value of up to €500 million [13] - Junshi Biosciences has signed a licensing agreement with Sandoz for its HLX13 monoclonal antibody, receiving an upfront payment of $31 million and potential milestone payments totaling $1.6 billion [14] Public Sentiment Alerts - Medici has announced that major shareholder Chen Jianhuang plans to reduce his stake by up to 2.23% between May 26 and August 25, 2025, due to personal funding needs [15]

华安证券股份有限公司 关于宁波长阳科技股份有限公司 2024年度持续督导工作现场检查报告 华安证券股份有限公司（以下简称"保荐机构"或"华安证券"）作为宁 波长阳科技股份有限公司（以下简称"长阳科技"或"公司"）2022年度向特 定对象发行股票并在科创板上市及持续督导的保荐机构，根据中国证监会《证 券发行上市保荐业务管理办法》以及《上海证券交易所上市公司自律监管指引 第11号——持续督导》等相关规定，对公司本持续督导期间的规范运作情况进 行了现场检查。现将本次现场检查情况报告如下： 一、本次现场检查的基本情况 （一）保荐机构 华安证券股份有限公司 （二）保荐代表人 何继兵、冯春杰 （三）现场检查时间 2025年4月21日至2025年4月22日 （四）现场检查人员 冯春杰、金宗辉 （五）现场检查内容 6、查阅公司定期报告、临时报告等信息披露文件； 7、核查本持续督导期间公司发生的关联交易、对外担保和对外投资情况； 8、检查公司、控股股东、实际控制人及董监高所做承诺及履行情况。 公司治理和内部控制情况、信息披露情况、公司的独立性以及与控股股东、 实际控制人及其他关联方资金往来情况、募集资金使用情况、关联交易、对外 ...

华安证券股份有限公司 关于宁波长阳科技股份有限公司 2024年度持续督导跟踪报告 华安证券股份有限公司（以下简称"保荐机构"、"保荐人"或"华安证券"） 作为宁波长阳科技股份有限公司（以下简称"长阳科技"或"公司"）2022年度 向特定对象发行股票并上市持续督导的保荐机构，根据《证券发行上市保荐业务 管理办法》、《上海证券交易所科创板股票上市规则》、《上海证券交易所上市 公司自律监管指引第11号——持续督导》等有关法律、法规的要求，负责长阳科 技本次股票发行上市后的持续督导工作，持续督导期间为2023年11月8日至2025 年12月31日。 2024年度，华安证券对长阳科技的持续督导工作情况总结如下： | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制度， | 保荐机构已建立并有效执行了持续督导 | | 1 | 并针对具体的持续督导工作制定相应的 | | | | | 工作制度，并制定了相应的工作计划 | | | 工作计划 | | | | 根据中国证监会相关规定，在持续督导工 | 保荐机构已与长阳科技签订保荐协议， | | | 作开始前 ...